Introduction
Hepatitis C virus (HCV) infection continues to be the leading cause of end-stage liver disease (ESLD) and indication for liver transplantation in the United States. Among liver transplant recipients with active HCV, recurrent HCV infection of the liver is universal, and subsequent progression to cirrhosis and decompensation is accelerated (1, 2) . Until recently, standard HCV treatment included pegylated-interferon (IFN) and ribavirin (RBV). In transplant recipients, these IFN-based regimens are poorly effective with sustained virologic response (SVR) rates of only 20-30%. In addition, these treatments are not well tolerated owing to significant side effects, leading to high rates of discontinuation and common adverse events, including death (3, 4) .
In 2011, the Food and Drug Administration (FDA) approved the first direct-acting antivirals (DAAs) for HCV, boceprevir and telaprevir. These newer DAAs improved nontransplant SVR rates, leading to cure in about 60-75% of patients (5); however, they were administered in combination with IFN and RBV, and thus, high rates of adverse events and treatment discontinuation were still observed in the transplant population with limited efficacy (6) (7) (8) . In November and December of 2013, the FDA approved two additional DAAs, sofosbuvir (SOF) and simeprevir (SIM), which in combination allowed for IFN-free regimens for the first time. Since December 2013, the FDA has approved several additional DAAs. These IFN-free DAA regimens have been shown to be effective and safe in multiple studies, including early compassionate access studies, phase 2 clinical trials, real-world observational cohorts and among liver transplant recipients (9) (10) (11) (12) (13) (14) (15) (16) .
Despite these advances in HCV treatment, the liver transplant waitlist continues to grow while the deceased donor pool remains stagnant (17) . Approximately 43% of the waitlist is HCV antibody positive, and an average of 4500 new HCV-positive candidates join each year (17) . This number is expected to increase as the HCV-positive birth cohort ages (18, 19) . The use of HCV-positive livers has the potential to mitigate this organ supply shortage. Potential concerns related to the use of HCV-positive livers include possible increased rates of infection, increased rates of rejection, progressive HCV-related fibrosis in the allograft or infection with a more difficult to treat HCV genotype. These potential complications may be alleviated with effective, well-tolerated HCV therapy. Little is known of the impact of IFN-free DAA regimens on the use of HCV-positive donor organs. The objectives of this study were to characterize the national landscape of HCV-positive liver donors and recipients and to identify changes in practice and outcomes in the era of DAAs.
Methods

Data source
This study used data from the Scientific Registry of Transplant Recipients (SRTR). The SRTR data system includes data on all donors, wait-listed candidates and transplant recipients in the United States, submitted by the members of the Organ Procurement and Transplantation Network (OPTN). The Health Resources and Services Administration (HRSA), US Department of Health and Human Services, provides oversight to the activities of the OPTN and SRTR contractors. The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy of or interpretation by the SRTR or the US government.
Study population
Using the SRTR, we identified 25 566 HCV-antibody-positive adult liver transplant recipients who received an HCV-positive (N = 2131) or HCVnegative (N = 23 435) deceased donor liver between January 1, 2005, and December 31, 2015. We compared HCV-positive liver utilization according to eras in which DAA therapies became available: IFN-only era (January 1, 2005, to December 31, 2010), early DAA/IFN era (January 1, 2011, to December 5, 2013) and IFN-free DAA era (December 6, 2013, to December 31, 2015) . HCV-positive livers transplanted in HCV-negative recipients were not included in the analysis (N = 53) given the limited number of cases. HCV-positive transplant recipients with missing, unknown or pending values for donor HCV status were excluded (N = 23). We identified 74 299 deceased donors recovered between January 1, 2005, and December 31, 2015, as captured by the SRTR. Mortality data were obtained via linkage to the Social Security Master Death File, which is lagged by 6 months; thus, all posttransplant outcomes analyses were censored on July 31, 2015. Deceased donors with missing, unknown or pending HCV serology status (N = 111) were excluded from the discard rate analysis.
Patient-level utilization of HCV-positive livers
The proportion of HCV-positive recipients who received HCV-positive livers was calculated for each year and era. We used modified Poisson regression to estimate the relative rate of receiving an HCV-positive liver in each era, adjusting for recipient age, sex, race, BMI, listing and transplant allocation Model for End-Stage Liver Disease (MELD), hepatocellular carcinoma (HCC), previous liver transplant, and donor age, race, sex, BMI, donation after cardiac death (DCD), history of diabetes and macrosteatosis above 40%. Models were also adjusted for tertile of Organ Procurement Organization (OPO) organ availability as captured by transplant rate per person-year of each OPO. This marker of organ availability has been described elsewhere and is a method used to account for geographic differences in access to transplantation within our patient population (20) . Utilization of HCV-positive livers began to increase during the early DAA/IFN era. Thus, we modeled the rate of receiving an HCVpositive liver as a function of time and included an interaction term between time and drug era to determine whether the increase in utilization in IFN-free DAA era was in excess of what would be expected given the existing trend.
Center-level utilization of HCV-positive livers
We identified 113 centers that had performed at least 10 liver transplants over the study period and calculated the proportion of HCV-positive recipients who received an HCV-positive liver in the IFN-free DAA era compared with the era in which any IFN was required (January 1, 2005, to December 5, 2013).
Changes in characteristics of transplanted HCV-positive liver donors
We compared the characteristics of HCV-positive donors used for transplantation in the IFN-free DAA era and the era in which any IFN was required. Chi-square tests were used to compare categorical variables and Wilcoxon rank-sum tests for nonparametric variables. To determine whether observed demographic shifts across drug eras were occurring within the overall donor pool or only among HCV-positive donors, we constructed unadjusted modified Poisson regression models with an interaction term between the characteristic (ie age, race, sex, BMI, DCD, history of diabetes) and drug era.
Changes in discard rate of livers from HCV-positive donors
We used modified Poisson regression to estimate the relative rate of discard (defined as recovered, but not transplanted) according to HCV status in each drug era (IFN-only, early DAA/IFN, and IFN-free DAA). To determine whether era had a statistically significant impact on the risk of HCV-positive discard, we built a modified Poisson regression model with interaction terms between donor HCV status and each drug era. Models were adjusted for donor age, sex, race, BMI, history of diabetes, macrosteatosis levels over 40% and DCD. Using the multivariable model, we estimated the number of HCV-positive livers that would have been discarded if they had been HCV-negative but otherwise had the same clinical characteristics. We compared this to the number of observed HCV-positive discards to estimate the number of discards in each era attributable to HCV-positive status.
Changes in all-cause graft loss among HCV-positive recipients, by donor HCV status
We built Cox proportional hazards models stratified by era to estimate the hazard of all-cause graft loss for recipients of HCV-positive livers compared to those who received HCV-negative livers censoring at (1)for recipient age, race, albumin, serum creatinine, international normalized ratio (INR), ABO incompatibility, malignant neoplasms (other than HCC), metabolic disease, other/unknown diagnosis, medical condition, portal vein thrombosis, previous abdominal surgery, previous liver transplant, previous malignancy, insurance type, dialysis in the last 2 weeks, life support and donor age, race, height, DCD, cold ischemia time, graft type (split/whole), desmopressin therapy, diuretic therapy, Centers for Disease Control and Prevention (CDC)-increased infectious risk, history of diuretics, cocaine use, cancer, and hypertension as recommended by SRTR risk adjustment model documentation released in December 2015.
Statistical analysis
Confidence intervals are reported as per the method of Louis and Zeger (21) . All statistical analyses were performed using Stata 14 SE (College Station, TX).
Results
Study population
HCV-positive recipients of HCV-positive livers were more likely to be African American (16% vs. 12%), more likely to have lower median allocation MELD at listing (17 vs. 19 ) and at transplant (22 vs. 25) , and less likely to have had a previous liver transplant (3% vs. 6%) than those who received an HCV-negative liver (Table 1) . HCVpositive liver donors were more likely to be between the ages of 31 and 55 years than HCV-negative donors (62% vs. 48%), more likely to be Caucasian (73% vs. 65%), and less likely to be DCD (2% vs. 6%). (23) (24) (25) (26) (27) (28) (29) (30) (31) 26 (23) (24) (25) (26) (27) (28) (29) <0.001 DCD (%) 6.0 2.1 <0.001 Center-level utilization of HCV-positive livers Of the 113 centers, 26 (23%) experienced a decrease in the proportion of HCV-positive recipients who received an HCV-positive liver between the IFN and IFN-free DAA eras, 9 (8%) had no change, and 76 (69%) experienced an increase (Figure 2A ). In the IFN-free DAA era, centers varied widely in their utilization of HCV-positive livers: 21 centers performed 0 HCV-positive liver transplants and 28 centers used HCV-positive livers for 20% or more of their HCV-positive recipients ( Figure 2B ).
Patient-level utilization of HCV-positive livers
(continued)
Changes in characteristics of transplanted HCV-positive liver donors
HCV-positive liver donors in the IFN-free DAA era were more likely to be Caucasian than HCV-positive liver donors in the IFN era (80% vs. 70%, p-value of interaction term = 0.001) ( HCV-positive livers in each respective drug era was attributable to HCV seropositivity.
Changes in all-cause graft loss among HCV-positive recipients There was no increased hazard of all-cause graft loss associated with receiving an HCV-positive liver versus 
Discussion
In this national study of hepatitis C antibody-positive liver transplant recipients, we found that the proportion who received an HCV-positive liver has increased significantly with the advent of IFN-free DAA regimens, from 6.9% to 16.9%. These changes were widespread, with the use of HCV-positive livers growing at the majority (69%) of transplant centers. We found that over the same time period the HCV-positive liver discard rate declined but is still 1.7 times the rate in comparable HCV-negative livers.
Even with these dramatic changes in utilization, allograft survival remains similar in HCV-positive recipients of HCV-positive and HCV-negative livers.
There are several possible explanations for the remarkable increase in the use of HCV-positive livers. Physician attitudes may have changed, driven by an increasing number of studies demonstrating the safety and efficacy of IFN-free DAA therapies in the liver transplant population (9, 10, 12, 13, 22, 23) . Interestingly, the increase in the proportion of HCV-positive livers used after 2010 precedes the availability of IFN-free combinations but aligns somewhat with the introduction of first-generation DAAs, boceprevir and telapravir. Although the use of these first DAAs was significantly limited by serious toxicities and drug-drug interactions with relatively poor outcomes among transplant patients, their introduction may have brought optimism to the field about agents in the pipeline or may have reflected a lag between the excitement about the first DAAs and the reporting of adverse outcomes. A survey of transplant physicians found that although 48% of providers were using these first-generation DAAs (protease inhibitors), 22% were going to wait for improved therapies before treating posttransplant, indicating awareness of future therapies and increasing comfort in use of DAAs in HCV-positive liver transplant recipients (24) . Long-term shifts in access to liver transplantation among all deceased donor liver transplantation (DDLT) recipients could also partially explain the increase we observed among HCV-positive recipients if declines in access have been leading to increased use of these marginal organs. However, the OPTN Annual Data Report has shown consistent transplant rates per 100 waitlist years among all DDLT recipients from 2004 to 2014 and a stable number of DDLTs among those with HCV as primary diagnosis over the same time period (17, 25) . Another possible explanation for the increase in utilization and decrease in discard of HCV-positive livers over time is a change in the HCV-positive deceased donor population. We found that HCV-positive liver donors used for transplantation were more likely to be younger, to be Caucasian and less likely to have diabetes in the recent era, in contrast to what has been observed in the overall donor population over time (26) . Saidi et al observed an increase in the proportion of deceased donors who were older than age 65, had BMI greater than 35 and had been donated after cardiac death (26) . Alongside the improving quality of HCV-positive donors, the declining quality of the overall donor pool may be an additional driver of increasing physician confidence in HCV-positive livers. In addition, a comparison of HCV-positive and HCV-negative livers used between 1994 and 2008 found that HCV-positive liver donors were more likely to be older and less likely to be Caucasian (27) . This unique shift among HCV-positive liver donors in the recent era may be related to the recent rise in injection drug use overdose deaths and acute HCV infections among young Caucasian individuals observed in the United States (28, 29) .
We found that, for HCV-positive recipients, receiving an HCV-positive liver was not associated with an increased risk of graft loss at 6 months or 1 year posttransplant in either era, consistent with earlier national studies using OPTN data (27, 30) . Although we were unable to determine viral load or genotype which may confer higher risk, a study by O'Leary et al showed that within a sample of HCV-antibody-positive deceased donors 50% were aviremic, underscoring our conclusions that some of these organs are high quality with comparable risk to HCVnegative organs (31) . These findings support use of HCV-positive livers for transplant in HCV-positive recipients with careful consideration of recipient and donor characteristics.
There are several limitations to this study. We could not directly evaluate treatment practices or receipt of IFNfree DAAs, and thus we considered HCV-positive DDLT recipients to be exposed to potential changes in practice if they were transplanted during the era in which these drugs were available. We hypothesized that overall availability of IFN-free DAAs would likely change transplant practices regarding the use of HCV-positive livers. We must also consider that recipients are reported as HCV antibody positive or negative in the SRTR, without indication of RNA positivity at transplant. If patients were treated pre-liver transplant and became RNA negative, they would remain HCV antibody positive, yet would be unlikely to receive an HCV-positive liver. Our findings may underestimate the proportion of actively infected HCV-positive liver transplant candidates who received an HCV-positive donor liver in the recent era. Furthermore, in our discard rate analysis we were only able to identify deceased donor livers recovered for transplantation; this excludes potential HCV-positive livers that were never recovered and therefore may underestimate the potential pool of HCV-positive organs. The data were not sufficient to explore the use of HCV-positive livers among HCV-negative recipients. Lastly, HCV genotype, virologic status and biopsy results of the deceased donor are not available through the SRTR; these factors may affect use and outcomes associated with HCV-positive donor livers.
The utilization of HCV-positive livers among HCV-positive recipients has increased dramatically in recent years, particularly since the introduction of highly effective DAA therapies, without any negative impact on posttransplant outcomes. Despite this, HCV-positive livers continue to be discarded at nearly twice the rate of comparable HCV-negative livers. Increased utilization of HCV-positive livers could increase access to transplantation for HCV-positive candidates and thereby attenuate the organ shortage for all candidates in need of a liver transplant. 
